[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2172069T3 - Derivado tetrapeptidico. - Google Patents

Derivado tetrapeptidico.

Info

Publication number
ES2172069T3
ES2172069T3 ES98115259T ES98115259T ES2172069T3 ES 2172069 T3 ES2172069 T3 ES 2172069T3 ES 98115259 T ES98115259 T ES 98115259T ES 98115259 T ES98115259 T ES 98115259T ES 2172069 T3 ES2172069 T3 ES 2172069T3
Authority
ES
Spain
Prior art keywords
chem
tetrapeptidic
derivative
dolastatin
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98115259T
Other languages
English (en)
Inventor
Kyoichi Sakakibara
Masaaki Gondo
Koichi Miyazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Teikoku Hormone Manufacturing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26525532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2172069(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teikoku Hormone Manufacturing Co Ltd filed Critical Teikoku Hormone Manufacturing Co Ltd
Application granted granted Critical
Publication of ES2172069T3 publication Critical patent/ES2172069T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A UN DERIVADO DE TETRAPEPTIDO REPRESENTADO POR LA FORMULA SIGUIENTE, O A UNA SAL DEL MISMO, EL CUAL TIENE UNA ACTIVIDAD CITOSTATICA MAYOR QUE LA DOLASTATINA 10, Y ES UTIL COMO AGENTE ANTITUMORAL: DONDE:
ES98115259T 1991-08-09 1992-08-06 Derivado tetrapeptidico. Expired - Lifetime ES2172069T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22353491 1991-08-09
JP22539191 1991-08-12

Publications (1)

Publication Number Publication Date
ES2172069T3 true ES2172069T3 (es) 2002-09-16

Family

ID=26525532

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92916961T Expired - Lifetime ES2144421T3 (es) 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico.
ES98115259T Expired - Lifetime ES2172069T3 (es) 1991-08-09 1992-08-06 Derivado tetrapeptidico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES92916961T Expired - Lifetime ES2144421T3 (es) 1991-08-09 1992-08-06 Nuevo derivado tetrapeptidico.

Country Status (13)

Country Link
US (2) US6004934A (es)
EP (2) EP0934950B1 (es)
JP (1) JP2618597B2 (es)
KR (2) KR0185440B1 (es)
AT (2) ATE215962T1 (es)
AU (2) AU662551B2 (es)
CA (1) CA2115355C (es)
DE (2) DE69232552T2 (es)
DK (2) DK0598129T3 (es)
ES (2) ES2144421T3 (es)
GR (1) GR3033397T3 (es)
SG (1) SG87056A1 (es)
WO (1) WO1993003054A1 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU669710B2 (en) * 1992-05-20 1996-06-20 Abbott Gmbh & Co. Kg Derivatives of dolastatin
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
CA2151953A1 (en) * 1992-12-16 1994-06-23 Andreas Haupt "dolostatin analog" (novel peptides, the preparation and use thereof)
JP3469580B2 (ja) * 1993-10-01 2003-11-25 帝国臓器製薬株式会社 新規なペプチド誘導体
US5599902A (en) * 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
KR100408909B1 (ko) * 1995-04-21 2004-04-29 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규펩티드유도체
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
CA2298639C (en) * 1997-09-24 2005-07-05 Erik J. Flahive Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
WO2001024763A2 (en) 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
WO2001041789A1 (fr) * 1999-12-07 2001-06-14 Santen Pharmaceutical Co., Ltd. Medicament contre les rhumatismes contenant un derive tetrapeptidique en tant qu'ingredient actif
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
KR20010079252A (ko) * 2001-06-27 2001-08-22 홍진의 주름형 드럼을 갖는 드럼 필터
DK1428530T3 (da) 2001-09-20 2008-12-01 Aska Pharm Co Ltd Tetrapeptidderivatkrystaller
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
ES2605443T3 (es) * 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
US8288352B2 (en) * 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
US7750116B1 (en) * 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
TWI439286B (zh) 2007-07-16 2014-06-01 Genentech Inc 抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
JP2010533495A (ja) 2007-07-16 2010-10-28 ジェネンテック， インコーポレイテッド ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
EP4427805A2 (en) 2008-01-31 2024-09-11 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates and methods of use
DK2842575T3 (da) 2008-03-18 2017-11-27 Seattle Genetics Inc Auristatin-lægemiddel-linker-konjugater
ES2625637T3 (es) 2010-02-12 2017-07-20 Pharmascience Inc. Compuestos de unión al dominio BIR IAP
PT3327027T (pt) 2011-11-17 2021-02-15 Pfizer Péptidos citotóxicos e seus conjugados de anticorpos e fármacos
ES2604766T3 (es) * 2012-09-20 2017-03-09 Celltrion, Inc. Derivado de dolastatina-10, procedimiento de producción del mismo y composición de fármaco anticanceroso que contiene el mismo
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
CA2930614A1 (en) 2013-12-17 2015-06-25 Novartis Ag Cytotoxic peptides and conjugates thereof
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
US20170190735A1 (en) * 2014-05-28 2017-07-06 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
CA2951368A1 (en) 2014-06-13 2015-12-17 Novartis Ag Auristatin derivatives and conjugates thereof
CA3069221C (en) 2014-09-23 2023-04-04 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA2993321A1 (en) 2015-07-24 2017-02-02 George Robert Pettit Quinstatin compounds
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
JP6858348B2 (ja) * 2016-03-29 2021-04-14 東レ株式会社 ペプチド誘導体及びその用途
CN110099682B (zh) 2016-11-14 2023-03-31 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US20230000995A1 (en) * 2019-10-28 2023-01-05 Ariel Scientific Innovations Ltd. Dolastatin 10 analog
JPWO2023033129A1 (es) 2021-09-03 2023-03-09

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4978744A (en) * 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US6034065A (en) * 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
US5635483A (en) * 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides

Also Published As

Publication number Publication date
DE69232552T2 (de) 2002-10-31
ES2144421T3 (es) 2000-06-16
AU2001095A (en) 1995-07-20
ATE215962T1 (de) 2002-04-15
GR3033397T3 (en) 2000-09-29
DE69230824D1 (de) 2000-04-27
CA2115355A1 (en) 1993-02-18
ATE190983T1 (de) 2000-04-15
SG87056A1 (en) 2002-03-19
DK0934950T3 (da) 2002-07-29
EP0934950A1 (en) 1999-08-11
EP0598129A1 (en) 1994-05-25
WO1993003054A1 (en) 1993-02-18
AU673487B2 (en) 1996-11-07
KR100202474B1 (en) 1999-06-15
EP0598129A4 (en) 1995-10-25
AU2415292A (en) 1993-03-02
US5654399A (en) 1997-08-05
KR0185440B1 (ko) 1999-04-01
DK0598129T3 (da) 2000-07-03
DE69232552D1 (de) 2002-05-16
JP2618597B2 (ja) 1997-06-11
EP0598129B1 (en) 2000-03-22
DE69230824T2 (de) 2000-07-27
CA2115355C (en) 2007-09-11
US6004934A (en) 1999-12-21
AU662551B2 (en) 1995-09-07
EP0934950B1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
ES2172069T3 (es) Derivado tetrapeptidico.
PT705833E (pt) Derivado de dc-89
FI914928A0 (fi) Hydroximetyl (metylencyklopentyl) puriner och -pyrimidiner.
ES2156155T3 (es) Derivado de pirazol.
SE9003476L (sv) Novel isoindole derivatives and salts thereof, process for producing the same and antitumor agent comprising the same
TW269687B (es)
ES2093037T3 (es) Derivados de beta-lactama y su preparacion.
DE69312776D1 (de) Fungizide 3,4-Diaryl-(5H)-Furan-2-Onederivate
ES2106058T3 (es) Derivados de benzamida.
DE69423339D1 (de) Epoxycyclohexendionderivat
ATE90685T1 (de) Disaccharidderivate.
FI963568A (fi) Peptidijohdannaisia
ATE182594T1 (de) Thiazolotriazol- und thiazolodiazolderivate mit fungizider aktivität
ES2093051T3 (es) Purinil- y pirimidil-tetrahidrofuranos.
ATE163005T1 (de) Saintopin derivate
ATE159253T1 (de) 2-thiazolylpyrroleakrylate mit fungizider wirkung

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 934950

Country of ref document: ES